Clinical study of the use of the new aminoglycoside tobramycin for therapy of infections due to gram-negative bacteria.
Tobramycin, a new aminoglycoside antimicrobial, was evaluated as therapy for infections due to Gram-negative bacilli in 15 seriously ill patients with underlying diseases. Three of 10 patients with Gram-negative bacteraemia also had a urinary tract infection. Two patients had a respiratory tract infection, one had cellulitis, one had a urinary tract infection, and another had septic phlebitis. Twelve patients were cured of their infections. Eosinophilia was observed in one patient, and another developed superinfection with Staphylococcus aureus after 6 days of tobramycin therapy. There were five isolates of Escherichia coli, five of Klebsiella sp., two of Pseudomonas sp., and one each of Enterobacter agglomerans, Serratia marcescens and Enterobacter cloacae. The average serum concentration of tobramycin 2 hr after a parenteral dose of 1.0 to 1.5 mg/kg was 5.1 microgram/ml; higher concentrations of tobramycin were present in urine. Tobramycin proved to be an effective antimicrobial in these patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D004755:Enterobacteriaceae / Q000302:isolation & purification; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011549:Pseudomonas / Q000302:isolation & purification; D014031:Tobramycin / Q000378:metabolism / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014031:Tobramycin